BRD3308 is primarily investigated for its potential therapeutic applications in the treatment of diabetes, particularly type 2 diabetes. It functions as a selective inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which plays a crucial role in the regulation of glucocorticoid metabolism. By inhibiting this enzyme, BRD3308 helps reduce the local activation of cortisol in tissues such as the liver and adipose tissue, thereby improving insulin sensitivity and glucose metabolism. This mechanism makes it a promising candidate for managing hyperglycemia and associated metabolic disorders. Additionally, its potential role in mitigating the adverse effects of glucocorticoid excess, such as obesity and insulin resistance, is being explored in preclinical studies.